Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis to hold fourth quarter and full year 2022 financial results webcast
07:05am, Wednesday, 08'th Feb 2023
Webcast scheduled for Wednesday, February 22 at 11:30 a.m. Eastern Time CARLSBAD, Calif.
Royalty Pharma agrees to buy Ionis Pharma royalties for $1.125 bln
09:24am, Monday, 09'th Jan 2023
Royalty Pharma Plc RPRX, -1.42% said Monday it agreed to pay up to $1.125 billion for drug royalties owned by Ionis Pharmaceuticals Inc. IONS, +1.00% . The royalties include Ionis' interests in Biogen
Ionis to present at 41st Annual J.P. Morgan Healthcare conference
07:05am, Wednesday, 04'th Jan 2023
CARLSBAD, Calif. , Jan. 4, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Brett P.
Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?
12:48pm, Friday, 09'th Dec 2022
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
01:33pm, Tuesday, 15'th Nov 2022
Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.
Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up
01:32pm, Thursday, 10'th Nov 2022
Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.
Ionis to present at upcoming investor conferences
07:05am, Thursday, 10'th Nov 2022
CARLSBAD, Calif. , Nov. 10, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Gu
Ionis Pharmaceuticals, Inc. (IONS) Q3 2022 Earnings Call Transcript
03:28pm, Wednesday, 09'th Nov 2022
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q3 2022 Earnings Conference Call November 9, 2022 11:30 AM ET Company Participants Julie Tepper - Investor Relations Brett Monia - Founder, CEO & Director Ri
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates
09:47am, Wednesday, 09'th Nov 2022
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Ionis to hold third quarter 2022 financial results webcast
07:05am, Wednesday, 26'th Oct 2022
CARLSBAD, Calif. , Oct. 26, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced a live webcast on Wednesday, November 9 th at 11:30 a.m.
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?
10:14am, Thursday, 20'th Oct 2022
Despite CRISPR stocks' enthusiasm, the risk of potential cures continues to cloud market projections for new gene-editing treatments moving through the pipeline toward FDA approval. The post CRISPR St
Ionis Pharmaceuticals Looks Good For The Long Term
03:19am, Wednesday, 19'th Oct 2022
Ionis has 3 approved therapies, but operates in the red. Approvals for tofersen and eplontersen are possible in 2023.
3 Biotech Stocks to Sell in October
03:59pm, Thursday, 29'th Sep 2022
This year will probably go down as the roughest year for investors since the financial recession in 2008. The S&P 500 has shed more than 20% of its value year-to-date as inflation and interest rates w
Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III
03:48pm, Friday, 23'rd Sep 2022
Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test
09:41am, Friday, 23'rd Sep 2022
Ionis stock tumbled Friday after partner AstraZeneca decided against sending their high cholesterol treatment into Phase 3 testing. The post Ionis Pharmaceuticals Nosedives After AstraZeneca Drops Hig
